[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659808":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":21,"studyPopulation":21,"armGroups":31,"interventions":44,"overallOfficials":21,"centralContacts":54,"locations":61,"responsibleParty":73,"collaborators":21,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":21,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":21,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":102,"whyStopped":21,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Riyadh Elm University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":21},[9],{"measure":10,"description":11,"timeFrame":12},"Pain intensity measured by the visual analoge scale VAS","using the Visual Analogue Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. VAS scores will be compared between the Botulinum Toxin Type A and triamcinolone groups.","2 weeks 4 weeks 6 weeks",[14,18],{"measure":15,"description":16,"timeFrame":17},"Headache","Headache-related impact will be assessed using the 6-item Headache Impact Test (HIT-6). Scores will be compared between the Botulinum Toxin Type A and triamcinolone groups.","2 weeks 4 weeks 6 weeks after injection",{"measure":19,"description":20,"timeFrame":17},"Sleep quality","Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). Scores will be compared between the Botulinum Toxin Type A and triamcinolone groups.",null,{"allocation":23,"interventionModel":24,"interventionModelDescription":21,"primaryPurpose":25,"observationalModel":21,"timePerspective":21,"maskingInfo":26},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":27,"maskingDescription":28,"whoMasked":29},"SINGLE","Participants are blinded to treatment allocation. The clinician administering the injection is aware of the assigned intervention because the preparation and administration of the two treatments differ.",[30],"PARTICIPANT",[32,38],{"label":33,"type":34,"description":35,"interventionNames":36},"Arm 1 botulinum toxin type 1","EXPERIMENTAL","Participants randomized to this arm will receive Botulinum Toxin Type A injection for the management of facial myofascial pain syndrome.",[37],"Drug: Botulinum Toxin A (Botox )",{"label":39,"type":40,"description":41,"interventionNames":42},"Arm 2 triamcinolone","ACTIVE_COMPARATOR","Participants randomized to this arm will receive triamcinolone injection for the management of facial myofascial pain syndrome.",[43],"Drug: Triamcinolone Acetonide",[45,50],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":21},"DRUG","Botulinum Toxin A (Botox )","Botulinum Toxin Type A will be administered by injection into the affected masticatory muscle trigger points according to the study protocol.",[33],{"type":46,"name":51,"description":52,"armGroupLabels":53,"otherNames":21},"Triamcinolone Acetonide","Triamcinolone acetonide will be administered by injection into the affected masticatory muscle trigger points according to the study protocol.",[39],[55],{"name":56,"role":57,"phone":58,"phoneExt":59,"email":60},"Albatool Saad Alahmari, BDS","CONTACT","+966545510103","000","Albatool.alahmari2024@student.riyadh.edu.sa",[62],{"facility":5,"status":21,"city":63,"state":64,"zip":21,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":21},"Riyadh","Riyadh Region","Saudi Arabia","SA",{"type":68,"coordinates":69},"Point",[70,71],46.72185,24.68773,{"lat":71,"lon":70},{"type":74,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Albatool Saad Alahmari","Principal investigator","100659808","phase-4-botulinum-toxin-type-a-versus-triamcinolone-for-facial-myalgia-100659808",false,"NCT07867379","Botulinum Toxin Type A Versus Triamcinolone for Facial Myalgia","Comparison of the Therapeutic Effects of Botulinum Toxin Type A and Triamcinolone Injection in Managing Facial Myalgia: A Single Blind Randomized Controlled Trial","Inclusion Criteria:\n\nInclusion Criteria:\n\n* Adults aged 18 to 60 years.\n* Diagnosed with Myofascial Pain Syndrome with active trigger points.\n* Ability and willingness to provide informed consent and adhere to the study procedures.\n\nExclusion Criteria:\n\nReceived any injection therapy within the past 6 months.\n\n* Neuromuscular disorders.\n* Pregnancy or breastfeeding.\n* Allergy to Botulinum Toxin or corticosteroids.\n* Refusal to provide informed consent.\n* Current use of systemic corticosteroids or muscle relaxants.\n* Individuals with disabilities who are unable to provide informed consent.","ALL","18 Years","60 Years",{"count":88,"type":89},56,"ESTIMATED","INTERVENTIONAL",[92],"PHASE4","This single-blind randomized controlled trial aims to compare the therapeutic effects of Botulinum Toxin Type A and triamcinolone injections in adults with facial myofascial pain syndrome. A total of 56 participants will be randomly allocated in a 1:1 ratio to receive either Botulinum Toxin Type A or triamcinolone injection. The primary outcome will assess pain intensity using the Visual Analogue Scale (VAS). Secondary outcomes will evaluate headache symptoms and sleep quality. The study aims to determine the comparative effectiveness of the two interventions in reducing pain and improving patient-reported outcomes.",[95],"Myofascial Pain Syndrome (MPS)",[97,98,99,100,101],"Facial myalgia","Orofacial pain","Triamcinolone","Trigger point injection","Botulinum toxin type A","NOT_YET_RECRUITING","2026-10-05",{"date":105,"type":106},"2026-10-09","ACTUAL",{"date":108,"type":89},"2026-10-11",{"date":110,"type":89},"2026-12-24",{"name":5,"class":6},1]